Targeting Regorafenib-induced Toxicity through Inhibition of Gut Microbial β-Glucuronidases

Regorafenib (Stivarga) is an oral small molecule kinase inhibitor used to treat metastatic colorectal cancer, hepatocellular carcinomas, and gastrointestinal stromal tumors. Diarrhea is one of the most frequently observed adverse reactions associated with regorafenib. This toxicity may arise from th...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:ACS Chem Biol
Egile Nagusiak: Ervin, Samantha M., Hanley, Ronan P., Lim, Lauren, Walton, William G., Pearce, Kenneth H., Bhatt, Aadra P., James, Lindsey I., Redinbo, Matthew R.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2019
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7254866/
https://ncbi.nlm.nih.gov/pubmed/31663730
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acschembio.9b00663
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak